Abstract
Over the last 4 decades, cardiac transplantation has become the preferred therapy for select patients with end-stage heart disease. Heart transplantation is indicated in patients with heart failure despite optimal medical and device therapy, manifesting as intractable angina, refractory heart failure, or intractable ventricular arrhythmias. This article provides an overview of heart transplantation in the current era, focusing on the evaluation process for heart transplantation, the physiology of the transplanted heart, immunosuppressive regimens, and early and long-term complications.
Keywords:
Cardiac transplantation; End-stage heart failure; Immunosuppression; Rejection.
Copyright © 2014 Elsevier Inc. All rights reserved.
MeSH terms
-
Allografts
-
Azathioprine / therapeutic use
-
Cardiotonic Agents / therapeutic use
-
Contraindications
-
Graft Occlusion, Vascular / diagnosis
-
Graft Occlusion, Vascular / etiology
-
Graft Occlusion, Vascular / therapy
-
Graft Rejection / prevention & control
-
Heart / innervation
-
Heart Failure / surgery*
-
Heart Transplantation / methods*
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Long-Term Care / methods
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / therapeutic use
-
Neoplasms / etiology
-
Opportunistic Infections / etiology
-
Opportunistic Infections / therapy
-
Postoperative Care / methods
-
Steroids / therapeutic use
Substances
-
Cardiotonic Agents
-
Immunosuppressive Agents
-
Steroids
-
Mycophenolic Acid
-
Azathioprine